V2890
Anti-VGLL4 (206-219) antibody produced in rabbit
IgG fraction of antiserum, buffered aqueous solution
Synonym(s):
Anti-Transcription cofactor vestigial-like protein 4 isoform 1, Anti-VGL-4
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
NACRES:
NA.41
biological source
rabbit
conjugate
unconjugated
antibody form
IgG fraction of antiserum
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
mol wt
antigen ~31 kDa
species reactivity
human
technique(s)
western blot: 1:500-1:2,000
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... VGLL4(9686)
General description
Vestigial-like 4 (VGLL4) belongs to the family of VGLL proteins and is characterized by two TDU domains at the C-terminal, unlike other members of the family. Vgl-4 is highly expressed in the nucleus. VGLL4 is encoded by the gene mapped to human chromosome 3p25.2.
Immunogen
synthetic peptide corresponding to amino acids 206-219 of human VGLL4
application
Yale Center for High Throughput Cell Biology IF-tested antibodies. Each antibody is tested by immunofluorescence against HUVEC cells using the Yale HTCB IF protocol. To learn more about us and Yale Center for High Throughput Cell Biology partnership, visit sigma.com/htcb-if.
Biochem/physiol Actions
Vestigial-like 4 (VGLL4) stimulates the apoptotic pathway by negatively regulating inhibitor of apoptosis proteins (IAPs). The encoded protein acts as a potential tumor suppressor and prognostic marker in gastric cancer and lung cancer. Knockdown of VGLL4 expression leads to progression of esophageal squamous cell carcinoma (ESCC).Therefore, restoring the function of VGLL4 can be a potential method for treating ESCC. Experimental studies states that VGLL4 is involved in regulation of cell mobility, migration and invasion.
Physical form
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Don't see the Right Version?
If you require a particular version, you can look up a specific certificate by the Lot or Batch number.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Integrated genomic characterization of oesophageal carcinoma.
Cancer Genome Atlas Research Network
Nature, 541, 169-175 (2017)
VGLL4 inhibits EMT in part through suppressing Wnt/?-catenin signaling pathway in gastric cancer.
Li H
Medical Oncology (Northwood, London, England), 32, 83-83 (2015)
Xiaowu Liu et al.
Oncology reports, 39(5), 2324-2332 (2018-03-08)
Bladder cancer (BCa) is the most common urological cancer, and more and more evidence suggests that microRNAs (miRNAs) play an important role in BCa pathogenesis. Aberrant miR-130b expression has been reported in several types of cancers. The aim of the present study was to
A novel inhibitor of apoptosis protein (IAP)-interacting protein, Vestigial-like (Vgl)-4, counteracts apoptosis-inhibitory function of IAPs by nuclear sequestration.
Jin HS
Biochemical and Biophysical Research Communications, 412, 454-459 (2011)
VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.
Zhang W
Cell Research, 24, 331-331 (2014)
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
